Comparative bioavailability of gefitinib ('Iressa', ZD1839) when administered as a dispersion preparation (by mouth or nasogastric tube) or tablet - a Phase I pharmacokinetic study.

被引：0
|
作者：
Cantarini, MV [1 ]
McFarquhar, T [1 ]
Smith, RP [1 ]
Marshall, AL [1 ]
机构：
[1] AstraZeneca, Macclesfield, Cheshire, England
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6102S / 6102S
页数：1
相关论文
共 4 条
  • [1] Phase I study results of Gefitinib (iressa; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma
    Reardon, DA
    Rich, J
    Quinn, J
    Vredenburgh, J
    Desjardins, A
    Sathornsumetee, S
    Gururangan, S
    Lyons, P
    Bigner, D
    Friedman, H
    NEURO-ONCOLOGY, 2005, 7 (03) : 312 - 312
  • [2] Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
    Nakagawa, K
    Tamura, T
    Negoro, S
    Kudoh, S
    Yamamoto, N
    Yamamoto, N
    Takeda, K
    Swaisland, H
    Nakatani, I
    Hirose, M
    Dong, RP
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2003, 14 (06) : 922 - 930
  • [3] A PHASE-I BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF HEXAMETHYLENE BISACETAMIDE (NSC-95580) ADMINISTERED VIA NASOGASTRIC TUBE
    WARD, FT
    KELLEY, JA
    ROTH, JS
    LOMBARDO, FA
    WEISS, RB
    LEYLANDJONES, B
    CHUN, HG
    CANCER RESEARCH, 1991, 51 (07) : 1803 - 1810
  • [4] Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: Results of a randomized, open-label, three-period crossover study in healthy volunteers
    Cantarini, MV
    McFarquhar, T
    Smith, RP
    Bailey, C
    Marshall, AL
    CLINICAL THERAPEUTICS, 2004, 26 (10) : 1630 - 1636
1